Business Wire - November 7, 2003
OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test has been awarded a 2003 Best of What's New award by Popular Science magazine in the Personal Health category. The award was announced on November 6, 2003, at the Best of What's New Showcase Event at Vanderbilt Hall in Grand Central Terminal in New York City.
OraQuick(R) is the first and only rapid, point-of-care test approved by the FDA to detect antibodies to HIV-1 in fingerstick and venipuncture whole blood specimens within approximately 20 minutes. OraSure received FDA approval of the OraQuick(R) test for use on fingerstick whole blood on November 7, 2002, and a CLIA (Clinical Laboratory Improvements Amendments of 1988) waiver on January 31, 2003, permitting its use by more than 180,000 sites in the United States, including outreach clinics, community-based organizations and physicians' offices. On September 5, 2003, OraSure received FDA approval of the OraQuick(R) test for use on venipuncture whole blood samples.
Each year, Popular Science reviews thousands of new products to select the 100 winners of the Best of What's New Awards for inclusion in the December Best of What's New issue of Popular Science, on newsstands November 12th. The annual awards recognize products and technologies that represent a significant step forward in twelve different categories, including Automotive Tech, Space & Aviation, Engineering, Cars, Computing, Gadgets, General Innovation, Home Entertainment, Home Tech, Personal Health, Photography and Recreation. More information is available at http://www.popsci.com/popsci/bown.
"Best of What's New is the culmination of a year's worth of searching, testing and deciding from among a huge range of products--all of which stand to change the way we live, work and play," said Scott Mowbray, editor in chief of Popular Science.
"This award validates the collaborative efforts of our research and development, manufacturing, regulatory and quality groups, who were responsible for bringing the OraQuick(R) Rapid HIV-1 test to the market," said Mike Gausling, Chief Executive Officer of OraSure Technologies. "The commitment and expertise of our team has been the driving factor behind OraSure's history of innovation in the diagnostic industry."
The 2003 Popular Science Best of What's New Award winners are being featured on Thursday, November 6th and Friday, November 7th at the Best of What's New Showcase Event at Vanderbilt Hall in Grand Central Terminal in New York. The showcase is a two-day consumer event open from 7:00 a.m. to 7:00 p.m. daily.
Founded in 1872, Popular Science(R) is the world's largest science and technology magazine, with a circulation of 1.45 million subscribers and a readership of more than seven million people. Popular Science(R) is published by Time4 Media(R), the world's leading publisher of leisure-time magazines.
About OraSure Technologies
OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.
OraSure Technologies is the leading supplier of oral-fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV-1. In addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to www.orasure.com.
CONTACT: OraSure Technologies
Ronald H. Spair, 610-882-1820
Investorinfo@orasure.com
www.orasure.com
or
William F. Bruckner, 610-882-1820
wbruckner@orasure.com
SOURCE: OraSure Technologies
031107
BW031104
Copyright © 2003 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .